BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext:IPN; ADR:IPSEY), today announced that abstracts of data regarding Somatuline® Depot (lanreotide) Injection 120 mg (referred to as Somatuline®) will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, May 29 – June 2, 2015. The data include a poster discussion of a new subgroup analysis of the Phase III CLARINET® study in patients with midgut neuroendocrine tumors (NETs).
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
